CRISPR Therapeutics Names Brendan Smith To Succeed Michael Tomsicek As CFO - Quick Facts

(RTTNews) - Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Thursday the appointment of Brendan Smith as Chief Financial Officer, effective today. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio.

Smith succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition.

Prior to CRISPR Therapeutics, Smith was the CFO & Corporate Strategy of Translate Bio, a company that was recently acquired by Sanofi for $3.2B. Smith is an accomplished executive with more than two decades of experience within high-growth biopharma environments where he made significant contributions in various operations and strategy positions.

Previously, as a Partner at Boston Consulting Group, Smith led integrated biopharma client engagements that included planning and executing on R&D strategy, operations, business development and deal diligence. Prior to that, he was VP, Head of Business Operations for Worldwide R&D at Pfizer, where he led financial and headcount planning across discovery and development operations.